Bharatiya Glob. (BGLOBAL)

Asset Play

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Current Price₹3.2
Market Cap₹5.07 Cr
P/E Ratio1.58
ROCE-1.77%
ROE3.84%
Dividend Yield0%
Profit Growth0%
Debt/Equity0.06
Sales Growth0%
Promoter Holding48.46%
52-Week Range₹2.62 — ₹4.6
SectorIT - Services
Book Value₹52.79

Strengths

Concerns

AI Analysis

Let me apply the same lens I use for any business. Bharatiya Glob is a micro-cap IT-enabled services company with a market cap of just ₹5 crore, yet its book value stands at ₹56.80 per share — roughly ₹87 crore of net assets. Buying at ₹3.26 gives a price-to-book of 0.06, a 94% discount to stated book value. That is a wide margin of safety on the balance sheet alone. But as Graham would warn, a cheap stock can be a value trap if the business cannot earn a decent return on its capital. Here, ROE is only 1.31%, and ROCE is negative at -1.77%. The latest quarter shows sales of ₹0 crore, while net profit is ₹1 crore. With no operating revenue, I cannot credit this as genuine operating strength; it may be non-operating or one-off in nature. Sales growth is zero, and the P/E of 0.00 makes the earnings figure meaningless for valuation. I also see no durable moat in a business with stagnant revenue and subpar returns. On the positive side, debt-to-equity is just 0.04, so the balance sheet is not leveraged, and promoters hold 48.46%, giving some alignment. Still, the Piotroski score of 5/9 is mediocre, and the 429% profit growth is from an extremely low base. This is not the wonderful business I seek. It is a classic asset play trading at a deep discount to book value, but the economics are poor. A cheap price does not always mean an intelligent investment. Unless management can generate real revenue, improve ROE, and deploy that book value productively, the discount may remain permanent. I would keep it on a watch list, not in a portfolio, until proven otherwise.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer